Cargando…

Comparing Efficacy of Preoperative neo-Adjuvant Chemotherapy and Surgery versus Surgery Alone in Patients with Resectable Gastroesophageal Cancer

BACKGROUND: Recent researches have led to find strategies to prevent relapse and to improve survival for gastric cancer patients, including preoperative neo-adjuvant approaches. However, the efficacy of some neo-adjuvant regimens including 5-fluorouracil, cisplatin, and docetaxel have been less inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Basi, Ali, Sohrabkhani, Shahab, Zamani, Farhad, Baghai-Wadji, Masoud, Rabiei, Neda, Razavi, Seyyed-Mohsen, Ajdarkosh, Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915424/
https://www.ncbi.nlm.nih.gov/pubmed/24505539
_version_ 1782302579884032000
author Basi, Ali
Sohrabkhani, Shahab
Zamani, Farhad
Baghai-Wadji, Masoud
Rabiei, Neda
Razavi, Seyyed-Mohsen
Ajdarkosh, Hossein
author_facet Basi, Ali
Sohrabkhani, Shahab
Zamani, Farhad
Baghai-Wadji, Masoud
Rabiei, Neda
Razavi, Seyyed-Mohsen
Ajdarkosh, Hossein
author_sort Basi, Ali
collection PubMed
description BACKGROUND: Recent researches have led to find strategies to prevent relapse and to improve survival for gastric cancer patients, including preoperative neo-adjuvant approaches. However, the efficacy of some neo-adjuvant regimens including 5-fluorouracil, cisplatin, and docetaxel have been less investigated. The present study evaluated the outcome and mid-term survival of patients with gastric cancer who undergoing this regimen. METHODS: In a randomized double-blinded controlled trial performed at the Firoozgar hospital in Tehran in 2011-12, 61 patients were randomly assigned to treatment (32 to neo-adjuvant chemotherapy with docetaxel, cisplatin and 5-fluorouracil (5-FU) before surgery and 27 to surgery alone). The present study tried to assess the efficacy of neoadjuvant chemotherapy regarding improvement of mid-term survival, complications, and R0 resection status. RESULTS: The two groups were matched in terms of gender, mean age, cancer location, and TNM staging. However, R0 resection in the former group was 85.7%; while this indicator in the isolated surgery group was significantly lower (61.5%). Regarding WHO performance, no significant difference was observed across the two groups. Patients in neo-adjuvant chemotherapy group were followed for mean follow-up time 10.32 months and those who categorized in isolated surgery group were followed for mean follow-up time 10.88 months. Mid-term mortality rate in the two groups was 14.3% and 15.4%, respectively (p = 0.866). In this regard, 3-, 6-, and 9-month survival rate in neo-adjuvant chemotherapy group was 96.4%, 89.3%, and 85.7%, respectively. These survival rates in the surgery group were 92.3%, 88.5%, and 84.6%, respectively. Multivariable logistic regression analysis showed that among all study variables, only R0 resection status could predict mid-term mortality. CONCLUSION: Neo-adjuvant chemotherapy and surgery compare to surgery alone more improve R0 resection status, but mid-term survival rate is similar in the two regiments. R0 resection status can effectively predict appropriate mid-term survival in undertreated patients.
format Online
Article
Text
id pubmed-3915424
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-39154242014-02-06 Comparing Efficacy of Preoperative neo-Adjuvant Chemotherapy and Surgery versus Surgery Alone in Patients with Resectable Gastroesophageal Cancer Basi, Ali Sohrabkhani, Shahab Zamani, Farhad Baghai-Wadji, Masoud Rabiei, Neda Razavi, Seyyed-Mohsen Ajdarkosh, Hossein Int J Hematol Oncol Stem Cell Res Original Article BACKGROUND: Recent researches have led to find strategies to prevent relapse and to improve survival for gastric cancer patients, including preoperative neo-adjuvant approaches. However, the efficacy of some neo-adjuvant regimens including 5-fluorouracil, cisplatin, and docetaxel have been less investigated. The present study evaluated the outcome and mid-term survival of patients with gastric cancer who undergoing this regimen. METHODS: In a randomized double-blinded controlled trial performed at the Firoozgar hospital in Tehran in 2011-12, 61 patients were randomly assigned to treatment (32 to neo-adjuvant chemotherapy with docetaxel, cisplatin and 5-fluorouracil (5-FU) before surgery and 27 to surgery alone). The present study tried to assess the efficacy of neoadjuvant chemotherapy regarding improvement of mid-term survival, complications, and R0 resection status. RESULTS: The two groups were matched in terms of gender, mean age, cancer location, and TNM staging. However, R0 resection in the former group was 85.7%; while this indicator in the isolated surgery group was significantly lower (61.5%). Regarding WHO performance, no significant difference was observed across the two groups. Patients in neo-adjuvant chemotherapy group were followed for mean follow-up time 10.32 months and those who categorized in isolated surgery group were followed for mean follow-up time 10.88 months. Mid-term mortality rate in the two groups was 14.3% and 15.4%, respectively (p = 0.866). In this regard, 3-, 6-, and 9-month survival rate in neo-adjuvant chemotherapy group was 96.4%, 89.3%, and 85.7%, respectively. These survival rates in the surgery group were 92.3%, 88.5%, and 84.6%, respectively. Multivariable logistic regression analysis showed that among all study variables, only R0 resection status could predict mid-term mortality. CONCLUSION: Neo-adjuvant chemotherapy and surgery compare to surgery alone more improve R0 resection status, but mid-term survival rate is similar in the two regiments. R0 resection status can effectively predict appropriate mid-term survival in undertreated patients. Tehran University of Medical Sciences 2013 /pmc/articles/PMC3915424/ /pubmed/24505539 Text en © 2013 Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Original Article
Basi, Ali
Sohrabkhani, Shahab
Zamani, Farhad
Baghai-Wadji, Masoud
Rabiei, Neda
Razavi, Seyyed-Mohsen
Ajdarkosh, Hossein
Comparing Efficacy of Preoperative neo-Adjuvant Chemotherapy and Surgery versus Surgery Alone in Patients with Resectable Gastroesophageal Cancer
title Comparing Efficacy of Preoperative neo-Adjuvant Chemotherapy and Surgery versus Surgery Alone in Patients with Resectable Gastroesophageal Cancer
title_full Comparing Efficacy of Preoperative neo-Adjuvant Chemotherapy and Surgery versus Surgery Alone in Patients with Resectable Gastroesophageal Cancer
title_fullStr Comparing Efficacy of Preoperative neo-Adjuvant Chemotherapy and Surgery versus Surgery Alone in Patients with Resectable Gastroesophageal Cancer
title_full_unstemmed Comparing Efficacy of Preoperative neo-Adjuvant Chemotherapy and Surgery versus Surgery Alone in Patients with Resectable Gastroesophageal Cancer
title_short Comparing Efficacy of Preoperative neo-Adjuvant Chemotherapy and Surgery versus Surgery Alone in Patients with Resectable Gastroesophageal Cancer
title_sort comparing efficacy of preoperative neo-adjuvant chemotherapy and surgery versus surgery alone in patients with resectable gastroesophageal cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915424/
https://www.ncbi.nlm.nih.gov/pubmed/24505539
work_keys_str_mv AT basiali comparingefficacyofpreoperativeneoadjuvantchemotherapyandsurgeryversussurgeryaloneinpatientswithresectablegastroesophagealcancer
AT sohrabkhanishahab comparingefficacyofpreoperativeneoadjuvantchemotherapyandsurgeryversussurgeryaloneinpatientswithresectablegastroesophagealcancer
AT zamanifarhad comparingefficacyofpreoperativeneoadjuvantchemotherapyandsurgeryversussurgeryaloneinpatientswithresectablegastroesophagealcancer
AT baghaiwadjimasoud comparingefficacyofpreoperativeneoadjuvantchemotherapyandsurgeryversussurgeryaloneinpatientswithresectablegastroesophagealcancer
AT rabieineda comparingefficacyofpreoperativeneoadjuvantchemotherapyandsurgeryversussurgeryaloneinpatientswithresectablegastroesophagealcancer
AT razaviseyyedmohsen comparingefficacyofpreoperativeneoadjuvantchemotherapyandsurgeryversussurgeryaloneinpatientswithresectablegastroesophagealcancer
AT ajdarkoshhossein comparingefficacyofpreoperativeneoadjuvantchemotherapyandsurgeryversussurgeryaloneinpatientswithresectablegastroesophagealcancer